Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-03-29
2011-03-29
Kim, Jennifer M (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07915285
ABSTRACT:
The present invention is directed to the use of ibudilast for treating addictions, including drug and behavioral addictions. In particular, ibudilast is used to diminish the dopamine-mediated reward associated with addictions and to treat withdrawal syndromes after discontinuance of addictive drug use or behavior.
REFERENCES:
patent: 5496836 (1996-03-01), Di Rocco et al.
patent: 6828349 (2004-12-01), Dewey et al.
patent: 6953774 (2005-10-01), Palmer et al.
patent: 2003/0195194 (2003-10-01), Gaeta et al.
patent: 2006/0008446 (2006-01-01), Watkins
patent: 2006/0106054 (2006-05-01), Nagasawa et al.
patent: 2006/0160843 (2006-07-01), Johnson et al.
patent: 2007/0072899 (2007-03-01), Johnson et al.
patent: 2007/0281966 (2007-12-01), Johnson et al.
patent: 2008/0114027 (2008-05-01), Johnson et al.
patent: 2008/0181876 (2008-07-01), Johnson et al.
patent: 2508194 (2004-06-01), None
patent: WO 99/64037 (1999-12-01), None
patent: WO 01/05422 (2001-01-01), None
patent: WO 03/104178 (2003-12-01), None
patent: WO 03/104203 (2003-12-01), None
patent: WO 2004/058713 (2004-07-01), None
patent: WO 2005/058304 (2005-06-01), None
patent: WO 2006/045505 (2006-05-01), None
patent: WO 2006/063048 (2006-06-01), None
patent: WO 2006/108671 (2006-10-01), None
patent: WO 2007/047978 (2007-04-01), None
Chihara et al. Inhibitory effect of ibudilast (KC-404) on the expression of the b2 integrin family on an eosinophilic cell line (EoL-1). Annals of Allergy, ASthma, &Immunology, Nov. 1998, vol. 81 pp. 448-450.
Murashima et al. Inhibitory effect of ibudilast (KC 404) on cyclic nucreotide phosphodiesterases. Janpanese Pharmacology and Therapeutics, 1998 vol. 26, No. 1 pp. 41-45, abstract.
Gibson, et al., “The Inhibitory Profile of Ibudilast Against the Human Phosphodiesterase Enzyme Family,”Eur J Pharmacology 538:39-42 (2006).
Gul, et al., “The Interaction Between IL-1B and Morphine: Possible Mechanism of the Deficiency of Morphine-Induced Analgesia in Diabetic Mice,”Pain 89:39-45 (2000).
Johnston, et al., “A Role for Prointlammatory Cytokines and Fractalkine in Analgesia, Tolerance, and Subsequent Pain Falicitation Induced by Chronic Intrathecal Morphine,”J Neurosci 24:7353-7365 (2004).
Mizuno, et al.,“Neuroprotective Role of Phosphodiesterase Inhibitor Ibudilast on Neuronal Cell Death Induced by Activated Microglia,”Neuropharmacology 46:404-411 (2004).
Narita, et al., “Direct Evidence of Astrocytic Modulation in the Development of Rewarding Effects Induced by Drugs of Abuse,”Neuropsychopharmacology 31:2476-2488 (2006).
Obernolte, et al., (The cDNA of a Human Lymphocyte Cyclic-AMP Phosphodiesterase (PDE IV) Reveals a Multigene Family, Gene 129:239-247 (1993).
Raghavendra, et al., “The Role of Spinal Neuroimmune Activation in Morphine Tolerance/Hyperalgesia in Neuropathic and Sham-Operated Rats,”J Neurosci 22:9980-9989 (2002).
Raghavendra, et al., “Attenuation of Morphine Tolerance, Withdrawal-Induced Hyperalgesia, and Associated Spinal Inflammatory Immune Responses by Propentofylline in Rats,”Neuropsychopharmacology29:327-334 (2004).
Rile, et al., “Potentiation of Ibudilast Inhibition of Platelet Aggregation in the Presence of Endothelial Cells,”Thrombosis Research 102:239-246 (2001).
Shavit, et al., “Interleukin-1 Antagonizes Morphine Analgesia and Underlies Morphine Tolerance,”Pain 115:50-59 (2005).
Song, et al., “The Involvement of Glial Cells in the Development of Morphine Tolerance,”Neuro Res 39:281-286 (2001).
Souness, et al., “Possible Role of Cyclic AMP Phosphodiesterases in the Actions of Ibudilast on Eosinophil Thromboxane Generation and Airways Smooth Muscle Tone,”Br ,J Pharmacol 111:1081-1088 (1994).
Sugiyama, et al., “SPECT Evaluation of Effect of Cerebral Vasodilator by the Subtraction Method Using Tc-99mHMPAO,”No To Shinkei 45(2):139-142 (1993)English Abstract.
Suzumura, et al., “Ibudilast Suppresses TNFa Production by Glial Cells Functioning Mainly as Type III Phosphodiesterase nhibitor in the CNS,”Brain Res 837:203-212 (1999).
Takuma, et al., “Ibudilast Attenuates Astrocyte Apoptosis Via Cyclic GMP Signalling Pathway in an In Vitro Reperfusion Model,”British Journal of Pharmacology 133:841-848 (2001).
Wakita, et al., “Ibudilast, a Phosphodiesterase Inhibitor, Protects Against White Matter Damage Under Chronic Cerebral Hyperfusion in the Rat,”Brain Res 992:53-59 (2003).
Watkins and Maier, “Beyond Neurons: Evidence That Immune and Glial Cells Contribute to Pathalogical Pain States,”Physiol Rev 82:981-1011 (2002).
Watkins and Maier, “Targeting Glia to Control Clinical Pain: An Idea Whose Time has Come,”Drug Disc Today 1(1):83-88 (2004).
Watkins, et al., “Glia: Novel Counter-Regulators of Opoid Analgesia,”Trends Neurosci 28(12):661-669 (2005).
Bloom & Bennett, “Mechanism of a reaction in vitro associated with delayed-type hypersensitivity,”Science 153:80-82 (1966).
Calandra & Roger, “Macrophage migration inhibitory factor: a regulator of innate immunity,”Nat Rev Immunol 3:791-800 (2003).
Calandra, et al., “Protection from septic shock by neutralization of macrophage migration inhibitory factor,”Nat Med 6:164-170 (2000).
Feng, et al., “Ibudilast, A Nonselective Phosphodiesterase Inhibitor, Regulates Th1/Th2 Balance and NKT Cell Subset in Multiple Sclerosis,”Mult Scler 10:494-498 (2004).
Fujimoto, et al., “Ibudilast, A Phosphodiesterase Inhibitor, Ameliorates Experimental Autoimmune Encephalomyelitis in Dark August Rat,”J Neuroimmunology 95:35-42 (1999).
Kawanokuchi, et al., “Effects of Interferon-Beta On Microglial Functions As Inflammatory and Antigen Presenting Cells in the Central Nervous System,”Neuropharmacology 46:734-742 (2004).
Koda, et al., “Up-Regulation of Macrophage Migration-Inhibitory Factor Expression After Compression-Induced Spinal Cord Injury in Rats,”Acta Neuropathol 108:31-36 (2004).
Narita, et al., “Role of Astrocytes in Rewarding Effects of Drugs Of Abuse,”Jpn J Neuropsychopharmacol 26:33-39 (2006)English Abstract.
Narita, et al., “Comparatice Pharmacological Profiles of Morphine and Oxycodone Under a Neuropathic Pain-Like State in Mice: Evidence for Less Sensitivity to Morphine,”Nature Neuropsychopharmacolog1-16 (2007)Online Article.
Santos & Morand, “The Role of Macrophage Migration Inhibitory Factor In The Inflammatory Immune Response And Rheumatoid Arthritis,”Wein Med Wochenschr 156:11-18 (2006).
Futaki, “Treatment of Meniere's Disease Comparison of Prednisolone and Ketas,”Practica Otologica Kyoto 83(9):1463-1471 (1990)English Abstract.
Itoh, et al, “A Therapeutic Strategy to Prevent Morphine Dependence and Tolerance by Coadministration of cAMP-Related Reagents with Morphine,”Methods and Findings in Experimental and Clinical Pharmacology 20(7):619-625 (1998).
Mamiya, et al., “Involvement of Cyclic AMP Systems in Morphine Physical Dependence in Mice: Prevention of Development of Morphine Depende by Rolipram, A Phosphodiesterase 4 Inhibitor,”Br J Pharmacol 132(5):1111-1117 (2001).
Nabeshima, et al., “Drug Dependence Formation Inhibitor: Comprising Phosphdoesterase Inhibitor, Preferably Rolipram, Especially for Combatting Narcotic Analgesic Dependence,” Database WPI, Derwent Publications, Ltd., London, GB, p. 7, AN 1997-506303 (1997).
Tsuru, et al., “Preference Test of 3-Isobutyryl-2-Isopopylpyrazolo [1,56-a] Pyridine (KC-404) On Rats,”Pharmacometrics36(6):449-457 1988English Abstract.
Kudo, et al., “General Pharmacological Activity of KC-404—Effect on Central Nervous System,” Kiso to Rinsho 19(11):5476-5484 (1985)Original Japanese Article With Attached Certified English Translation.
Hutchinson, et al., “Opoid-Induced Glial Activation: Mechanisms of Activation and Implic
Johnson Kirk W.
Rothblum Watkins Linda May
Foley & Lardner LLP
Kavarana Malcolm J.
Kim Jennifer M
Medicinova, Inc.
The Regents of the University of Colorado
LandOfFree
Method for treating drug and behavioral addictions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating drug and behavioral addictions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating drug and behavioral addictions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2712091